Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Addison Advisors LLC

Addison Advisors LLC raised its position in Edwards Lifesciences Co. (NYSE:EW) by 915.1% during the third quarter, HoldingsChannel reports. The firm owned 18,038 shares of the medical research company’s stock after buying an additional 16,261 shares during the quarter. Addison Advisors LLC’s holdings in Edwards Lifesciences were worth $1,190,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Crewe Advisors LLC purchased a new position in Edwards Lifesciences in the first quarter valued at approximately $28,000. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $29,000. Webster Bank N. A. purchased a new stake in Edwards Lifesciences in the second quarter valued at approximately $39,000. Peoples Bank KS purchased a new position in shares of Edwards Lifesciences during the third quarter worth approximately $40,000. Finally, Versant Capital Management Inc increased its holdings in shares of Edwards Lifesciences by 206.3% in the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 326 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on EW. StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, July 25th. Evercore ISI reduced their target price on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. The Goldman Sachs Group decreased their target price on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Finally, Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $66.23 on Monday. The company has a current ratio of 3.46, a quick ratio of 2.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The stock has a market capitalization of $39.06 billion, a P/E ratio of 9.56, a PEG ratio of 3.72 and a beta of 1.12. The business’s fifty day moving average price is $67.59 and its 200 day moving average price is $76.80.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter last year, the firm posted $0.59 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 8.9% compared to the same quarter last year. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at $3,101,530.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 41,250 shares of company stock worth $2,746,988. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.